Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00743938 · ClinicalTrials.gov registry record · Phase 2
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
NCT00743938 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 141 participants.
The verdict
NCT00743938, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
Study Summary
The purpose of this study is to improve disease control and survival for patients who were treated with chemotherapy using BMS-690514 over erlotinib
Interventions
- DRUG Erlotinib
- DRUG BMS-690514
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00743938
The ClinicalTrials.gov registry entry for NCT00743938 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT00743938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00743938 about?
NCT00743938 is a clinical study titled "A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC". The purpose of this study is to improve disease control and survival for patients who were treated with chemotherapy using BMS-690514 over erlotinib
What is the current status of trial NCT00743938?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2009-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00743938?
The interventions under investigation include: Erlotinib (DRUG), BMS-690514 (DRUG).
Who is sponsoring clinical trial NCT00743938?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.